Dr Joe Conner - Chief Scientific Officer
Dr. Joe Conner has 30 years experience in scientific research, and over 20 of these have been associated with the Herpes Simplex virus. He possesses extensive expertise in virology, molecular and cell biology and substantial experience in autoimmunity and antibody engineering.
He has pursued research studies in the department of Clinical Biochemistry at the University of Glasgow, at the Hospital of Pontchaillou (France), at the MRC Virology Unit (Glasgow) and at Glasgow Caledonian University. Additionally he has been Consultant Molecular Biologist to Viragen (Scotland), published over 50 peer-reviewed papers, and is author of several granted patents.
Dr Alex Graham - VP Translational Medicine
Dr. Alex Graham has more than 30 years of experience as a scientist in the biotechnology and pharmaceutical sector, having most recently worked as a Principal Scientist for AstraZeneca.
He has led several small molecule discovery projects and most recently was responsible for the Genomics Facility for AstraZeneca Oncology. He was also responsible for introducing relevant new technologies into the Oncology business, specifically in the areas of biomarkers and translational medicine.
Alex joined Virttu in 2008 and has been closely involved in the planning,management and analysis of Virttu's clinical studies.
Robert Spavin - VP Legal Affairs
Robert joined VIRTTU in 2003 as Legal Counsel responsible for the company's legal and intellectual property affairs. Qualifying as a solicitor with City of London firm Herbert Smith in 1996, he subsequently specialised in IP law at leading IP firm Bird & Bird.
He is experienced in the development of growth technology companies, patent management and regulatory affairs.
VIRTTU's lead programme SEPREHVIR®, a unique oncolytic immunotherapy, shows the potential to transform treatment and target many forms of cancer effectively.
We are conducting clinical studies in a wide range of cancer types in leading medical centres in the USA and Europe.